Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pardes Biosciences, Inc. PRDS
$1.89
+$0.03 (1.61%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
120347565.00000000
-
week52high
6.86
-
week52low
0.75
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.34814300
-
EPS
-1.66000000
-
Last Dividend
0.00000000
-
Next Earnings Date
14 мар 2023 г. в 20:01
Описание компании
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 16 авг 2022 г. |
| SVB Leerink | Outperform | 15 мар 2022 г. | |
| Jefferies | Buy | 18 янв 2022 г. | |
| JMP Securities | Market Outperform | 13 дек 2022 г. | |
| SVB Leerink | Outperform | Outperform | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Brusky Sean P. | A | 156250 | 156250 | 01 февр 2023 г. |
| HENSON HEIDI | A | 156250 | 156250 | 01 февр 2023 г. |
| Kearney Brian | A | 156250 | 156250 | 01 февр 2023 г. |
| Lacy Elizabeth H. | A | 156250 | 156250 | 01 февр 2023 г. |
| WIGGANS THOMAS G | A | 562500 | 562500 | 01 февр 2023 г. |
| Brusky Sean P. | A | 21000 | 21000 | 08 дек 2022 г. |
| WIGGANS THOMAS G | A | 50000 | 12500 | 05 дек 2022 г. |
| WIGGANS THOMAS G | A | 37500 | 12500 | 02 дек 2022 г. |
| Foresite Capital Management V, LLC | A | 12809810 | 637420 | 01 дек 2022 г. |
| WIGGANS THOMAS G | A | 25000 | 25000 | 01 дек 2022 г. |
Новостная лента
Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
GlobeNewsWire
01 февр 2023 г. в 08:30
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of COVID-19, announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 10:40 a.m. PT / 1:40 p.m. ET.
10 Top Penny Stocks To Watch With High Short Interest This Week
PennyStocks
31 янв 2023 г. в 14:30
More short squeeze penny stocks to watch before February 2023. The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Pardes Biosciences to Present at Jefferies London Healthcare Conference
GlobeNewsWire
01 ноя 2022 г. в 08:30
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 8:00 a.m. GMT / 12:00 a.m. PT.
Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
12 сент 2022 г. в 08:30
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that management will participate in a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 7:30 a.m. PT / 10:30 a.m. ET in New York City.
Pardes Biosciences to Present at Jefferies Global Healthcare Conference
GlobeNewsWire
01 июн 2022 г. в 08:30
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022 at 8:30 a.m. PT / 11:30 a.m. ET.